Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
about
Anti-vascular endothelial growth factor for proliferative diabetic retinopathyThe Vitreomacular Interface in Diabetic RetinopathyPathophysiology of diabetic retinopathyA review of anti-VEGF agents for proliferative diabetic retinopathyTreatment of diabetic retinopathy: Recent advances and unresolved challengesEndothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy.Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema.The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Pharmacotherapies for diabetic retinopathy: present and future.Diabetic retinopathy: treatment and prevention.Pharmacologic therapies for diabetic retinopathy and diabetic macular edemaEffects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathyNew Therapeutic Approaches in Diabetic Retinopathy.Current treatments for radiation retinopathy.Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.Treatment of proliferative diabetic retinopathy with anti-VEGF agents.Combined Tractional and Rhegmatogenous Retinal Detachment in Proliferative Diabetic Retinopathy in the Anti-VEGF EraPEDF regulates vascular permeability by a γ-secretase-mediated pathway.Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy.Apelin in epiretinal membranes of patients with proliferative diabetic retinopathy.Vitreous levels of vascular endothelial growth factor in eyes with anterior hyaloidal fibrovascular proliferation.Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy.Antiangiogenic therapy for ischemic retinopathies.Pathophysiology and treatment of diabetic retinopathy.Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.Current concepts in intravitreal drug therapy for diabetic retinopathy.Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy.Hypoxia-induced retinal neovascularization in zebrafish embryos: a potential model of retinopathy of prematurity.Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy.A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery.Bevacizumab for neovascular ocular diseases.Vascular endothelial growth factor in eye disease.The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy.Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy.The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic SubjectsIntravitreal bevacizumab: an analysis of the evidence.Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients.
P2860
Q24187858-1C497BEB-6160-476C-A221-5744CA178F54Q26783404-061417B6-F176-4A4B-961B-2873B159E11AQ26865897-E6544B77-426C-4038-AAD0-776410D08CDFQ27025643-74A12114-C276-48E4-B805-87AFA45D4DA2Q28067491-4DF9B5B1-B496-43E7-8A00-BB3245625671Q30433579-DD46EDA4-14BF-4D1C-B3CF-6CCEC360FCA7Q30874452-8B72D226-F107-4206-A8E0-CCBD3DA5B292Q31061150-FF5CD94E-494B-413E-A7DD-0A8AC14D0238Q33294882-F9CFE507-8E93-439C-86A8-884D22D56FF0Q33302529-6696F331-72D9-4877-BC79-5E4F00DD5603Q33492340-96C99CE0-F81D-493E-9DB0-EEA6D215E3BFQ33521675-5727CF5B-2C96-44CC-B8DB-2A5FB81A6AD6Q33583037-69483401-176E-45FB-BE51-F85AC9FE6767Q33665180-F0C150C8-E750-40D0-B0AE-FCE41A316E51Q33805314-D066591E-39C3-4F30-A898-87BBCFE167E5Q33812021-C17996A8-AB13-4729-A426-AA8482865819Q33905676-509B3072-B639-49F0-8B54-64D3D450E2B3Q33939170-A0793263-C08D-4E70-B73D-C98E53C404E4Q33949871-9AC46850-8475-4782-84EF-B778CA7AC7CFQ33990716-710FC17C-25B2-4C39-8871-2584B3EEEE92Q34161125-63CC1C74-01C1-469B-BC80-DAC10539C0B6Q34211317-8A274A95-242D-4693-A5A5-418E1297EB08Q34295974-8AD0991D-29FB-456B-B9D4-01E727F03A33Q34528134-B35717EA-7578-4A22-A284-911607C0860FQ34621295-96080B5E-AD59-4B7D-BC5E-47971865042DQ34957884-BA1BAAC6-9338-4ED5-8454-BE251B28044DQ34987495-79BE6ED7-70D2-4430-9EC5-51C25B11A1F3Q35180490-EE106F95-7E3F-44EC-A3BB-79412ED46C23Q35610708-E36F944A-5E86-438A-82A1-B85B9F041F57Q35923669-8867FFD9-B3F1-49ED-88C9-5E08189CFE28Q36342984-C051E579-C31E-40E6-827C-6F0DBE5CD2DAQ36758847-9FA51224-524F-4FEF-B590-F3261162E9FCQ36929380-B3B1E78E-588C-4165-9ACA-BF50AE02A22BQ36977441-90203B6C-6BEF-4FF6-AE7D-20FDC55E02B2Q37053882-0EDE9EA1-3D48-4657-AE1E-FBC38839809FQ37058905-AC4F24CD-F48C-47F1-9EA9-47F0E7466169Q37084522-CBCBD704-15B8-48EE-91B5-F00BABA9E3E1Q37545245-46B011C0-60CC-4637-A912-CEA73626D01AQ37577410-020F2A19-EED3-403D-B527-A4D28CD33064Q37677989-00041A8F-6445-41A7-841F-1AAD9E1EB7DC
P2860
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@ast
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@en
type
label
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@ast
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@en
prefLabel
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@ast
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@en
P2093
P1433
P1476
Intravitreal bevacizumab (Avas ...... tic retinopathy (IBEPE study).
@en
P2093
Daniela Calucci
Ingrid U Scott
Léssia P Cintra
Rogério A Costa
P304
P356
10.1097/01.IAE.0000246884.76018.63
P577
2006-11-01T00:00:00Z